GlobeNewsWire
19 Oct 2026, 12:45 UTC · 1h ago
Impact · against what's priced in
OneMedNet is scaling its distribution model through a 12th channel partner agreement, expanding its global reach into pharmaceutical intelligence. This shift toward an indirect sales model provides a modest catalyst for revenue growth and margin expansion.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
OneMedNet signed a channel partner agreement with a global pharmaceutical intelligence provider to distribute its U.S.-sourced clinical data worldwide.
Newannounced today Oct 19, 2026
More positive than 81% of claims this week
This agreement marks OneMedNet's 12th channel partner agreement to date.
New
Continue reading
5 related stories
The signing of a 12th channel partner to distribute U.S.-sourced clinical data worldwide suggests a transition toward a high-leverage sales model that can accelerate global market penetration.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
So whatScaling the partner network to 12 suggests a shift toward a high-leverage indirect sales model to improve operating margins.
More positive than 57% of claims this week
Which stocks this story touches
More positive than 90% of ticker scores this week
The company announced its 12th channel partner agreement, expanding its global reach and market penetration.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
24m ago
+6.0%
Price agrees with the score
$4.78 vs $4.51 close before publication (Oct 16) · not market-adjusted
ONMD chart →
